Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The effects of repetitive transcranial magnetic stimulation on sleep in individuals with substance use disorders: A systematic review.

Journal of psychiatric research·2026
Same author

Investigating Physical Exercise and Cognitive Training Effects on Cognition and Brain Health in Men and Women with Heart Failure: The ReCARDIO Trial.

CJC open·2026
Same author

Review of current research practices in social and structural determinants of health data collection in Canadian longitudinal cohorts of aging and dementia.

Neurobiology of aging·2026
Same author

Oral body temperature and cerebrospinal fluid pTau181 in older adults at increased risk of Alzheimer's disease.

Neurobiology of aging·2026
Same author

Influence of an AQP4 haplotype and sleep duration on early Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Educating nursing students to meet the mental health needs of vulnerable populations: a narrative review.

Frontiers in public health·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Nolan-Patrick Cunningham1,2, Jennifer Tremblay-Mercier1,2, Andrée-Ann Baril3,4

  • 1Douglas Mental Health University Institute, Montreal, QC, Canada.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
Resumen

Este estudio investiga Lemborexant y TCC-I para el riesgo de la enfermedad de Alzheimer (EA). Lemborexant puede reducir los biomarcadores de EA y mejorar la cognición, y la TCC-I potencia estos efectos.

Palabras clave:
LemborexantTCC-IEnfermedad de Alzheimerbiomarcadoresfunción cognitivaensayo clínico

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia
  • Medicina del Sueño
  • Farmacología

Sus antecedentes:

  • El mal sueño es un factor de riesgo modificable para el desarrollo y la progresión de la enfermedad de Alzheimer (EA).
  • Las intervenciones del sueño, incluidos los antagonistas duales de los receptores de orexina (DORA) como Lemborexant y la Terapia Cognitivo Conductual para el Insomnio (TCC-I), muestran potencial para mejorar los perfiles de riesgo de la EA.
  • Los DORA pueden disminuir la fosforilación tau y los niveles de beta-amiloide (Aβ).

Objetivo del estudio:

  • Evaluar el impacto de Lemborexant, con o sin TCC-I, en los biomarcadores sanguíneos de la EA y la función cognitiva en personas en riesgo de demencia por EA.
  • Evaluar la eficacia de Lemborexant y la TCC-I como posibles intervenciones para mitigar el riesgo de EA.

Principales métodos:

  • Un ensayo clínico aleatorizado, doble ciego y de 12 meses de duración en el que participaron 220 personas (de 50 a 90 años) con síntomas de insomnio.
  • Los participantes se aleatorizan en cuatro grupos: Lemborexant, Lemborexant + TCC-I, placebo o placebo + TCC-I.
  • Se proporciona educación sobre higiene del sueño a todos los participantes.

Principales resultados:

  • Los resultados primarios incluyen cambios en la p-tau181 plasmática y la puntuación modificada del Compuesto Cognitivo Preclínico de Alzheimer.
  • Los resultados secundarios implican cambios en la p-tau217 plasmática, el líquido cefalorraquídeo (LCR) Aβ 42/40, la p-tau181 del LCR y las medidas objetivas del sueño mediante electroencefalograma (EEG).
  • Los resultados anticipados sugieren que Lemborexant puede reducir la p-tau181 plasmática y mejorar el sueño y la cognición, y la TCC-I puede potenciar estos beneficios.

Conclusiones:

  • Esta investigación mejorará la comprensión del potencial terapéutico de las intervenciones del sueño en la prevención de la EA.
  • El estudio tiene como objetivo aclarar la influencia de los DORA en los biomarcadores de la EA y la función cognitiva.
  • Los hallazgos pueden informar futuras estrategias para el manejo del riesgo de la EA a través de un mejor sueño.